A new era for hemophilia B treatment

Jason A. Taylor, Rebecca Kruse-Jarres

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


In this issue of Blood, Santagostino et al, in their phase 3 study, demonstrate efficacy and safety of recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) which, along with the other 2 extended half-life FIX products, heralds a new era for the treatment of hemophilia B.

Original languageEnglish (US)
Pages (from-to)1734-1736
Number of pages3
Issue number14
StatePublished - Apr 7 2016

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'A new era for hemophilia B treatment'. Together they form a unique fingerprint.

Cite this